Sponsor / Institution

Sunnybrook Health Sciences Centre

Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.

All Programs Therapeutics Devices

Open filtered programs

Programs

linked to organization

Strong Evidence

0 status confirmed

Details Checked

0 open data checks

Company / Institution Links

0 / 3

industry vs non-industry records

Competitive Density

Pipeline Velocity

Completion Signal

Programs by Stage

Phase 21

Phase 41

Not applicable1

Trial / Program Status

Active1

Unknown2

Modality Mix

Small Molecule2

Behavioral/Rehabilitation1

Indication Coverage

Hearing Loss3

Cisplatin-Induced Hearing Loss2

Sensorineural Hearing Loss2

Ototoxicity1

Tinnitus1

Program Types

Therapeutic2

Procedure/Rehab1

Population Tags

adult3

cisplatin-ototoxicity2

bilateral1

cancer1

cochlear-implant1

otoprotection1

rehabilitation1

tinnitus1

Strong-Evidence Records

0 records

No strong-evidence records are linked to this organization yet.

Checked Records With Caveats

3 checked · 0 open checks

Teleconference auditory training services study

Details checked

Behavioral/RehabilitationNot applicableUnknown

Prospective study comparing remote teleconference-based auditory training services with face-to-face auditory training for cochlear implant recipients.

Data checks: institution-led-study, registry-only-evidence

Intratympanic N-Acetylcysteine Cisplatin Otoprotection Studies

Details checked

Small MoleculePhase 4Unknown

Registry-backed institution-led studies evaluating intratympanic N-acetylcysteine before cisplatin chemotherapy to prevent or reduce cisplatin-induced ototoxic hearing loss.

Data checks: institution-led-study, registry-only-evidence

Sunnybrook sodium thiosulfate plus mannitol cisplatin otoprotection study

Details checked

Small MoleculePhase 2Active

Intravenous sodium thiosulfate plus mannitol administered 4-8 hours after cisplatin chemotherapy to reduce adult cisplatin-induced ototoxic hearing loss.

Data checks: institution-led-study, active-recruiting